Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4525 - Clinical impact of molecular positive lymph node status in colorectal cancer

Date

09 Sep 2017

Session

Poster display session

Presenters

Nariaki Matsuura

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

N. Matsuura1, N. Tomita2, M. Inomata3, K. Murata4, S. Hayashi5, Y. Miyake6, S. Igarashi7, M. Itabashi8, T. Kato9, S. Noura10, T. Furuhata11, H. Ozawa12, I. Takemasa13, M. Yasui14, H. Takeyama15, O. Okamura16, H. Yamamoto17

Author affiliations

  • 1 Surgery, Osaka International Cancer Institute, 541-8567 - Osaka/JP
  • 2 Surgery, Hyogo College of Medicine, Nishinomiya/JP
  • 3 Gastroenterological And Pediatric Surgery,, Faculty of Medicine, Oita University, Oita/JP
  • 4 Surgery, Kansai Rosai Hospital, Amagasaki/JP
  • 5 Digestive Surgery, Nihon University Hospital, Tokyo/JP
  • 6 Surgery,, Osaka Minato Central Hospital, Osaka/JP
  • 7 Pathology, Tsuboi Cancer Center Hospital, Utsunomiya/JP
  • 8 Gastroenterology, Tokyo Women's Medical University, Tokyo/JP
  • 9 Colorectal Surgery, National Hospital Organization Osaka National Hospital, Osaka/JP
  • 10 Surgery, Osaka Rosai Hospital, Sakai/JP
  • 11 Gastroenterological And General Surgery, St. Marianna University Toyoko Hospital, Tokyo/JP
  • 12 Colorectal Surgery, Tochigi Cancer Center, Utsunomiya/JP
  • 13 Surgery, Surgical Oncology And Science, Sapporo Medical University School, Sapporo/JP
  • 14 Surgery, Osaka International Cancer Institute, Osaka/JP
  • 15 Surgery, Minoh City Hospital, Minoh/JP
  • 16 Surgery, Suita Municipal Hospital, Suita/JP
  • 17 Molecular Pathology, Graduate School of Medicine, Osaka University, Suita/JP
More

Resources

Abstract 4525

Background

Accurate evaluation of lymph node (LN) status is important for prediction of prognosis and decision of postoperative adjuvant therapy in cancer patients. Histopathological diagnosis, usually used for this evaluation, has shortcoming of lower sensitivity due to observing only small portion of whole lymph node. To overcome it we developed a new molecular diagnostic system, one-step nucleic acid amplification (OSNATM) assay which measures cytokeratin (CK) 19 mRNA expression level in whole lymph node and reported the usefulness in colorectal cancer (CRC) as well as in breast, gastric and lung cancers. According to our recent study in CRC, 17.6% of stage II (histologically node negative) patients were found to be molecularly positive in OSNA assay. In this multicenter trial, we investigated the clinical impact of OSNA positive cases.

Methods

Patients with cN0 and cN1 CRC in 11 Japanese representative medical institutes were enrolled. All LNs were examined histopathologically by using one-slice hematoxylin-eosin staining. In addition, half of the LN, which could be cut into half (average, 9.8 LN/patient), was examined by OSNA assay. Patients were classified in accordance with the UICC staging criteria and OSNA results, and the 3-year disease-free survival (DFS) of each cohort was analyzed.

Results

We enrolled 204 patients with CRC, excluded 9 patients, and analyzed 195 patients (stage I: n = 50, stage II: n = 71, stage III: n = 74). Of the patients with node-negative CRCs, only one was OSNA positive at stage I, and 11 were OSNA positive at stage II. OSNA-positive stage II cases had much lower 3-year DFS rate than OSNA negative ones (p = 0.005). Among various clinical and pathological parameters, only OSNA status was a significant prognostic factor for 3-year DFS in stage II CRC cases (p = 0.025).

Conclusions

This prospective multicenter study showed for the first time a prognostic value of OSNA positivity in stage II CRC. This assay is useful for selecting high-risk patients with stage II CRC. Further study to determine the treatment strategy for patients with OSNA-positive stage II CRC is necessary.

Clinical trial identification

Legal entity responsible for the study

OICI

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.